Merck Hep C Drug Zepatier OK'd

Merck & Co. gained the FDA's go-ahead on Jan. 28 to market Zepatier (elbasvir and grazoprevir) as a treatment for adults with chronic hepatitis C virus (HCV) genotypes (GTs) 1 or 4 infection, with or without ribavirin (RBV).